nandrolone decanoate has been researched along with Cardiovascular Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Börjesson, A; Choong, E; Ekström, L; Gårevik, N; Lehtihet, M | 1 |
| Hartgens, F; Keizer, HA; Kuipers, H; Rietjens, G; Wolffenbuttel, BH | 1 |
| Bourgeois, MO; Bray, GA; Greeson, C; Lovejoy, JC; Macchiavelli, R; Partington, C; Rood, JC | 1 |
2 trial(s) available for nandrolone decanoate and Cardiovascular Diseases
| Article | Year |
|---|---|
Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
Topics: Adult; Anabolic Agents; Androgens; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Double-Blind Method; Exercise; Humans; Injections, Intramuscular; Lipoprotein(a); Male; Nandrolone; Nandrolone Decanoate; Prospective Studies; Self Administration; Triglycerides | 2004 |
Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women--a clinical research center study.
Topics: Adipose Tissue; Androgen Antagonists; Androgens; Body Composition; Cardiovascular Diseases; Female; Hormones; Humans; Nandrolone; Nandrolone Decanoate; Obesity; Postmenopause; Risk Factors; Spironolactone | 1996 |
1 other study(ies) available for nandrolone decanoate and Cardiovascular Diseases
| Article | Year |
|---|---|
Impact of single-dose nandrolone decanoate on gonadotropins, blood lipids and HMG CoA reductase in healthy men.
Topics: Adult; Anabolic Agents; Apolipoproteins B; Cardiovascular Diseases; Cholesterol; Follicle Stimulating Hormone; Gonadotropins; Humans; Hydroxymethylglutaryl CoA Reductases; Lipids; Luteinizing Hormone; Male; Middle Aged; Nandrolone; Nandrolone Decanoate; Risk Factors; RNA, Messenger | 2016 |